



<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>		Application Number	10/607,836
		Filing Date	June 27, 2003
		First Named Inventor	Bhat, Vinayak D.
		Art Unit	3738
		Examiner Name	
Total Number of Pages in This Submission	4	Attorney Docket Number	020460-001691US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard Cited References EP Search Report
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Townsend and Townsend and Crew LLP Nena Bains Reg. No. 47,400
Signature	
Date	4-8-04

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Landon Clark		
Signature		Date	4-8-04

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 020460-001691US

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On

4-8-04

TOWNSEND and TOWNSEND and CREW LLP

By:

*London Clark*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

BHAT, VINAYAK D. et al.

Application No.: 10/607,836

Filed: June 27, 2003

For: DEVICES DELIVERING  
THERAPEUTIC AGENTS AND  
METHODS REGARDING THE SAME

Examiner: Unassigned

Art Unit: 3738

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37  
CFR §1.97 and §1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


The references cited on attached form PTO/SB/08A are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Nena Bains', with a stylized, flowing script.

Nena Bains  
Reg. No. 47,400

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
NB/lle  
60180467 v1



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/607,836	
			Filing Date	June 27, 2003	
			First Named Inventor	Bhat, Vinayak D.	
			Art Unit	3738	
			Examiner Name	Unassigned	
Sheet	1	of	1	Attorney Docket Number	020460-001691US

U.S. PATENT DOCUMENTS+					
		Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Examiner Initials*	Cite No. <sup>1</sup>	Number Kind Code <sup>2</sup> (if known)			
	0001	US-5,521,184	05-28-1996	Zimmermann	
	0002	US-6,096,070	08-01-2000	Ragheb et al.	
	0003	US-6,214,901 B1	04-10-2001	Chudzik et al.	
	0004	US-6,344,035 B1	02-05-2002	Chudzik et al.	
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	0005	EP	0923953	A2	06-23-1999	Schneider, Inc.		<input type="checkbox"/>
	0006	WO	00/010622	A1	03-02-2000	Cook, Inc.		<input type="checkbox"/>
	0007	WO	02/092091	A1	11-21-2002	Novartis AG, et al.		<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	0008	MATSUSHITA, HIDEITSUGU, et al.; "Hypoxia-Induced Endothelial Apoptosis Through Nuclear Factor-kB (NF-kB)- Mediated bcl-2 Suppression In Vivo Evidence of the Importance of NF-kB in Endothelial Cell Regulation;" <u>Circulation Research</u> ; May 12, 2000; pp. 974-981.	
	0009	MORISHITA, RYUICHI, et al.; "In Vivo Transfection of cis Element "Decoy" Against Nuclear Factor-kB Binding Site Prevents Myocardial Infarction;" <u>Nature Medicine</u> ; August 1997; pp. 894-899, Volume 3; Number 8.	
	0010	SAWA, YOSHIKI, et al.; "A Novel Strategy for Myocardial Protection Using In Vivo Transfection of cis Element 'Decoy' Against NFkB Binding Site Evidence for a Role of NFkB in Ischemia-Reperfusion Injury;" <u>Gene Therapy for Myocardial Protection Supplement II Circulation</u> ; November 4, 1997; pp. II-280 - II-285; Volume 96, Number 9.	
	0011	YOSHIMURA, S., et al.; "Inhibition of Intimal Hyperplasia after Balloon Injury in Rat Carotid Artery Model using cis- element 'Decoy' of Nuclear Factor-kB Binding Site as a Novel Molecular Strategy;" <u>Gene Therapy</u> ; 2001; pp. 1635- 1642; Nature Publishing Group.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.